Regarding T2D medications, 50% of patients were GLP-1 RAs users (semaglutide 55.8%, dulaglutide 40.4%, exenatide 3.8%) and the other half took other medications, mostly metformin (90.2%) and sodium-glucose cotransporter-2 (SGLT2) inhibitors (31.4%) either alone or in combination. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.